Frontida BioPharm, Inc. Launches CAT.one Testing to Support Abuse-Deterrent Product Development
Frontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the launch of its new Category 1 (CAT.ONETM) in vitro testing and evaluation services to support development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.
View full press release